All data are based on the daily closing price as of April 30, 2026
s

Synmosa Biopharma

4114.TWO
0.97 USD
-0.01
-1.02%

Overview

Last close
0.97 usd
Market cap
491.58M usd
52 week high
1.31 usd
52 week low
0.88 usd
Target price
1.17 usd

Valuation

P/E
18.5843
Forward P/E
N/A
Price/Sales
2.5168
Price/Book Value
1.7803
Enterprise Value
479.99M usd
EV/Revenue
2.4537
EV/EBITDA
12.6041

Key financials

Revenue TTM
195.62M usd
Gross Profit TTM
84.66M usd
EBITDA TTM
34.35M usd
Earnings per Share
0.05 usd
Dividend
0.03 usd
Total assets
445.55M usd
Net debt
18.02M usd

About

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale retail of environmental drugs; and import and export of related businesses. The company was founded in 1959 and is based in Taipei, Taiwan.
  • Symbol
    4114.TWO
  • Exchange
    TWO
  • Isin
    TW0004114004
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Banson Lin
  • Headquarter
    Taipei
  • Web site
    https://www.synmosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top